Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs

Journal of Occupational and Environmental Medicine

Volumn 52, Issue 10, 2010, Pages 1028-1034

  McDiarmid, Melissa A ^a   Oliver, Marc S ^a   Roth, Tracy S ^a   Rogers, Bonnie ^b   Escalante, Carmen ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIMETABOLITE; GYRASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PROBE; DRUG EXPOSURE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MALE; OCCUPATIONAL EXPOSURE; ONCOLOGY;

EID: 77958021321     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181f73ae6     Document Type: Article

References (50)

1. Rowley JD, Golomb HN, Vardiman J. Acute leukemia after treatment of lymphoma. N Engl J Med. 1977;297:1013.
2. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities [review]. Leukemia. 2002;16:2177-2184. (Pubitemid 35331831)
3. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2008;99:1909-1912.
4. Falck K, Grohn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979;1:1250-1251.
5. Anderson RW, Puckett WH, Dana WJ, Nguyen TV, Theiss JC, Matney TS. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982;39:1881-1887.
6. Nguyen TV, Theiss TC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982;42:4792-4796.
7. Rogers B, Emmett EA. Handling antineoplastic agents: urine mutagenicity in nurses. Image J Nurs Sch. 1987;19:108-113.
8. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm. 1996;53:2713-2723.
9. Sorsa M, Anderson D. Monitoring of occupational exposure to sytostatic anticancer agents. Mutat Res. 1996;355:253-261.
10. Sessink PJ, Bos RP. Drugs hazardous to health-care workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999;20:347-359.
11. Testa A, Giachelia M, Palma S, et al. Occupational exposure to antineoplastic agents induces a high level of chromosome damage. Lack of an effect of GST polymorphisms. Toxicol Appl Pharmacol. 2007;223:46-55.
12. Cornetta T, Padua L, Testa A, et al. Molecular biomonitoring of a population of nurses handling antineoplastic drugs. Mut Res. 2008;638:75-82.
13. Laffon B, Teixeira JP, Silva S, et al. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am J Ind Med. 2005;48:128-136.
14. US Department of Labor, Occupational Safety and Health Administration (OSHA). Work Practice Guidelines for Personnel Dealing With Cytotoxic (Antineoplastic) Drugs. OSHA Publication 8-1.1. Washington, DC: Occupational Safety and Health Administration; 1986.
15. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm. 1985;42:131-137.
16. Occupational Safety and Health Administration. OSHA Instruction TED (Training and Education Directive), 1.15 Directorate of Technical Support: Controlling Occupational Exposure to Hazardous Drugs. 1Washington, DC: Occupational Safety and Health Administration; 1995.
17. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049.
18. American Society of Health System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2006;63:1172-1193.
19. National Institute for Occupational Safety and Health. NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. DHHS (NIOSH) Publication No. 2004-165. Washington, DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 2004.
20. Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56:354-365.
21. Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2002;76:5-10.
22. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1996;70:205-208.
23. Sessink PJ, Van de Kerkhof MC, Anzion R, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed technicians: is skin absortion and important exposure route? Arch Environ Health. 1994;49:165-169.
24. Sessink PJ, Wittenhorst B, Anzion R, Bos RP. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997;52:240-244.
25. Fransman W, Peelen S, Hilhorst S, Roeleveld N, Heederik D, Kromhout H. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg. 2007;51:231-239.
26. Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789:169-209.
27. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to antineoplastic durgs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000;7:551-560.
28. Nieuwenhuijsen MJ, ed. Exposure Assessment in Occupational and Environmental Epidemiology. New York, NY: Oxford University Press, Inc, New York; 2003:144-145, 253-260.
29. Zhang L, Rothman N, Wang Y, et al. Increased aneusomy and long arm deletion of chromosomes 5 and 7 in the lymphocytes of Chinese workers exposed to benzene, 1. Carcinogenesis. 1998;19:1955-1961. (Pubitemid 28521937)
30. Zhang L, Rothman N, Wang Y, et al. Benzene increases aneuploidy in the lymphocytes of exposed workers: a comparison of data obtained by fluorescence in situ hybridization in interphase and metaphase cells. Environ Mol Mutagen. 1999;34:260-268.
31. Larson RA, LeBeau MM. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005;153-154:187-195.
32. International Commission on Radiological Protection (ICRP). Available at: http://www.icrp.org/educational-area.asp. Accessed November 1, 2008.
33. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons, Inc; 2000:138-140.
34. McCullagh P, Nelder JA. Monographs and Statistics and Applied Probability 37. Generalized Linear Models. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 1999.
35. Gojo I, Karp JE. The impact of biology on the treatment of secondary AML. Cancer Treat Res. 2001;108:231-255.
36. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83:2780-2786.
37. Westendorf J, Marquardt H, Marquardt H. Structure-activity relationship of anthracycline-induced genotoxicity in vitro. Cancer Res. 1984;44:5599-5604.
38. Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res. 1996;355:171-208.
39. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to human health. Available at: http://monographs.iarc.fr/ENG/Classification/index.php. Accessed July 1, 2009.
40. Mitelman F, Brandt L, Nilsson PG. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings and bone marrow chromosomes in acute non-lymphocytic leukemia. Blood. 1978;52:1229-1237.
41. Golomb HM, Alimena G, Rowley JD, Vardiman JW, Testa JR, Sovik C. Correlation of occupation and karyotype in adults with acute non-lymphoctyic leukemia. Blood. 1982;60:404-411.
42. Reich SD. Antineoplastic agents as potential carcinogens: are nurses and pharmacists at risk? Cancer Nurs. 1981;4:500-502.
43. Biological markers in environmental health research. Committee on Biological Markers of the National Research Council. Environ Health Perspect. 1987;74:3-9.
44. McDevitt MA, Condon M, Stamberg J, Karp JE, McDiarmid MA. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance. Mutat Res. 2007;629:24-31.
45. Qumsiyeh MD, Li P. Molecular biology of cancer: cytogenetics. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:77-90.
46. Zhang L, Rothman N, Wang Y, et al. Interphase cytogenetics of workers exposed to benzene, 1. Environ Health Perspect. 1996;104(suppl 6):1325-1329. (Pubitemid 27046163)
47. Smith MT, Zhang L, Wang Y, et al. Increased translocations and anuesomy in chromosomes 8 and 21 among workers exposed to benzene. Cancer Res. 1998;58:2176-2181.
48. Hayes RB, Zang L, Yin S, et al. Genotoxic markers among butadiene polymer workers in China. Carcinogenesis. 2000;21:55-62.
49. Sram RJ, Beskin O, Binkiva B, Rossner P, Smerhovsky Z. Cytogenetic analysis using fluorescence in situ hybridization (FISH) to evaluate occupational exposure to carcinogens. Toxicol Lett. 2004;149:335-344.
50. Connor TH, DeBord D, Pretty J, et al. Evaluation of antineoplastic drug exposure in healthcare workers at three U. S. cancer centers. J Occup Environ Med. 2010;52:1019-1027.